GS-9667
Code | Size | Price |
---|
TAR-T27439-1mg | 1mg | £177.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27439-5mg | 5mg | £328.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27439-10mg | 10mg | £448.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27439-25mg | 25mg | £691.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27439-50mg | 50mg | £938.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27439-100mg | 100mg | £1,243.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27439-500mg | 500mg | £2,416.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
GS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).
CAS:
618380-90-8
Formula:
C21H24FN5O4S
Molecular Weight:
461.51
Pathway:
Neuroscience|GPCR/G Protein
Purity:
0.98
SMILES:
O[C@@H]1CCC[C@H]1Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CSc2ccccc2F)[C@@H](O)[C@H]1O
Target:
Adenosine Receptor
References
1. Staehr PM, Dhalla AK, Zack J, Wang X, Ho YL, Bingham J, Belardinelli L. Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol. 2013 Apr;53(4):385-92. doi: 10.1002/jcph.9. Epub 2013 Feb 20. PubMed PMID: 23427000.
2. Yang M, Chu R, Chisholm JW, Doege H, Belardinelli L, Dhalla AK. Adenosine A? receptors do not play a major role in the regulation of lipogenic gene expression in hepatocytes. Eur J Pharmacol. 2012 May 15;683(1-3):332-9. doi: 10.1016/j.ejphar.2012.03.012. Epub 2012 Mar 16. PubMed PMID: 22449383.
3. Shearer J, Severson DL, Su L, Belardinelli L, Dhalla AK. Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo. J Pharmacol Exp Ther. 2009 Jan;328(1):306-11. doi: 10.1124/jpet.108.143594. Epub 2008 Oct 24. PubMed PMID: 18952888.
4. Dhalla AK, Santikul M, Chisholm JW, Belardinelli L, Reaven GM. Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats. Diabetes Obes Metab. 2009 Feb;11(2):95-101. doi: 10.1111/j.1463-1326.2008.00902.x. Epub 2008 May 20. PubMed PMID: 18494808.